Unknown

Dataset Information

0

Sex differences in gene expression with galactosylceramide treatment in Cln3?ex7/8 mice.


ABSTRACT: BACKGROUND:CLN3 disease is caused by mutations in the CLN3 gene. The purpose of this study is to discern global expression patterns reflecting therapeutic targets in CLN3 disease. METHODS:Differential gene expression in vehicle-exposed mouse brain was determined after intraperitoneal vehicle/Galactosylceramide (GalCer) injections for 40 weeks with GeneChip Mouse Genome 430 2.0 arrays. RESULTS:Analysis identified 66 genes in male and 30 in female brains differentially expressed in GalCer-treated versus vehicle-exposed Cln3?ex7/8 mice. Gene ontology revealed aberrations of biological function including developmental, cellular, and behavioral processes. GalCer treatment altered pathways of long-term potentiation/depression, estrogen signaling, synaptic vesicle cycle, ErbB signaling, and prion diseases in males, but prolactin signaling, selenium compound metabolism and steroid biosynthesis in females. Gene-gene network analysis highlighted networks functionally pertinent to GalCer treatment encompassing motor dysfunction, neurodegeneration, memory disorder, inflammation and astrogliosis in males, and, cataracts, inflammation, astrogliosis, and anxiety in females. CONCLUSIONS:This study sheds light on global expression patterns following GalCer treatment of Cln3?ex7/8 mice. Understanding molecular effects of GalCer on mouse brain gene expression, paves the way for personalized strategies for treating this debilitating disease in humans.

SUBMITTER: Makoukji J 

PROVIDER: S-EPMC7531864 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6389635 | BioStudies
2019-01-01 | S-EPMC7233413 | BioStudies
2018-01-01 | S-EPMC6080763 | BioStudies
1000-01-01 | S-EPMC4381334 | BioStudies
2020-09-11 | E-MTAB-9232 | ArrayExpress
1000-01-01 | S-EPMC3955974 | BioStudies
2014-01-01 | S-EPMC4106830 | BioStudies
2020-01-01 | S-EPMC7453105 | BioStudies
2011-01-01 | S-EPMC3191043 | BioStudies
2012-01-01 | S-EPMC3368842 | BioStudies